Celcuity

Celcuity LT Debt/Equity

The Long-Term Debt to Equity Ratio of Celcuity (CELC) as of Nov 11, 2026 is 3.20. In the previous year, Long-Term Debt to Equity Ratio was 0.85 — a change of 278.67% (higher).

LT Debt/Equity

3.20

YoY

278.67%

Last updated:

Long-Term Debt to Equity Ratio of Celcuity is 2025 3.20 . Long-Term Debt to Equity Ratio of Celcuity was 2024 0.85 . It decreases by 278.67% higher compared to the previous year.

The Celcuity LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2021
0.21 USD
Jan 1, 2022
0.26 USD
Jan 1, 2023
0.26 USD
Jan 1, 2024
0.85 USD
Jan 1, 2025
3.20 USD
The Celcuity LT Debt/Equity history
YEARLT Debt/EquityYoY
3.20+278.67%
0.85+218.99%
0.26+1.32%
0.26+22.86%
0.21+29,012.26%
0.00-6.76%
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Long-Term Debt to Equity Ratio of Celcuity is 3.20 in 2025.

Long-Term Debt to Equity Ratio of Celcuity changed from 0.85 to 3.20, representing a 278.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Celcuity since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Celcuity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celcuity

All Key Metrics — Celcuity